SillaJen IPO Part 3 - Competitive Strengths of Product (Pexa-Vec)
* In Part 3 (as below), I summarized the competitive strengths of product (Pexa-Vec).SillaJen's Pexa-Vec is an advanced liver cancer treatment...
249 Views
SillaJen IPO Part 2 - Growth Potential & Appropriate Valuation Level
* In Part 2 (as below), I summarized the growth potential and appropriate valuation level of SillaJen.Apparently, not many people are doubtful...
253 Views
Celltrion Healthcare IPO, Unlikely to Have Owner Premium Factor
Celltrion Healthcare, Celltrion (068270)’s overseas sales and marketing unit, decided to be listed in KOSDAQ (instead of Korea’s main bourse) as...
322 Views
SillaJen's December IPO: Valuation, Growth Expectation and IPO Timing
SillaJen Biotherapeutics (established in 2006) is indeed a rare breed in Korean pharmaceutical world. It is not a generic drug maker. It is not a...
3.4k Views
Alpha Generation Through Share Buybacks in Korea: August & September 2023
In this insight, we discuss the alpha generation through companies that announced share buybacks in Korea in August and September 2023.
595 Views